
9. The combination of claim 8 wherein Combination Index value of the synergistic effect is less than about 0.8.

10. A compound of formula Ia or a pharmaceutically acceptable salt thereof as defined in claim 1, for therapeutic use for improving the quality of life of a patient treated for a hyperproliferative disorder with erlotinib or a pharmaceutically acceptable salt thereof.

11. ~~A method for treating a hyperproliferative disorder in a mammal comprising, administering to the mammal~~ Use of a combination of, a) a compound of Formula Ia:



Ia,

or a pharmaceutically acceptable salt thereof; and b) erlotinib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a hyperproliferative disorder in a mammal.

12. The combination of a) a compound of formula Ia or a pharmaceutically acceptable salt thereof as defined in claim 1; and b) erlotinib or a pharmaceutically acceptable salt thereof for treating a disease or condition modulated by AKT kinase.

13. The use of a compound of formula Ia or a pharmaceutically acceptable salt thereof as defined in claim 1 in the preparation of a medicament for the treatment of a hyperproliferative disorder in a mammal, wherein erlotinib or a pharmaceutically acceptable salt thereof is to be administered to the mammal.

14. A kit comprising a compound of formula Ia or a pharmaceutically acceptable salt thereof as defined in claim 1, a container, and a package insert or label indicating the administration of the compound of formula Ia with erlotinib or a pharmaceutically acceptable salt thereof for treating a hyperproliferative disorder.